Great question by Jason Westin, MD #SOHO2025 #lymsm session: when will #AI Machine Learning models be used in real time in the clinic? Jonas Paludo Mayo Clinic Comprehensive Cancer Center the time is now.

Had an awesome time at #SOHO2025 — great talks, caught up with friends, and always love being back in Houston. Already looking forward to the next one! 🩸🌇 #MedTwitter SUNY Upstate IM Residency Nikhil Vojjala, MD Avi Harisingani, MD Society of Hematologic Oncology (SOHO)

Grateful to Shaji Kumar & Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 for their mentorship on this study. Hoping collaborations across these nations will strengthen myeloma care in the region #Myeloam #MedTwitter

Register and attend: The 2nd Annual Kyle Barlogie Plasma Cell Disorders Symposium featuring top myeloma experts from Mayo Clinic and Memorial Sloan Kettering Cancer Center Info and registration link: web.cvent.com/event/3197041a… Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Shaji Kumar

Fantastic Precursors Panel this morning in Toronto at #IMS25 #mmsm

#IMS25 Great Meet The Expert talk by Ben Derman on MRD in #Mmsm Risk vs benefit Who can stop treatment Active surveillance post discontinuation

Shaji Kumar presenting the revised response criteria! Much needed changes coming, assessment especially the role of functional imaging and use of MRD. 👏👏 reduced role of 24h urine and simultaneous >sequential confirmation! #IMS25 @MayoMyeloma Vincent Rajkumar

Congratulations Team IMS for hosting a crucial breakfast session on improving drug availability & accessibility in LMICs—home to 70% of myeloma patients. Congrats Uday Yanamandra representing IMAGe. A big step toward better health for all myeloma patients. #IMS

One slide summarized it all! By ⁦Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰⁩ at #IMS2025 #IMS25

Let’s bust the “myth” of big data (#RWD)! - ⁦Darryl Leong⁩ at the Cancer Centers Survivorship Research Forum (#CCSRF25), hosted by @danafarber & ⁦Alicia Morgans, MD, MPH⁩

Congratulations to this year's Young Investigator Award recipients at #IMS25.

MGIP is persistent in 84% of cases. MGIP derived from clonal plasma cells #mmsm

Advances in Myeloma. 2025 Edition Key takeaways from #IMS25 1) Early intervention is here: Given recent EU approval of daratumumab for high risk smoldering myeloma in Europe, and NCCN category 1 recommendation in the US, ~55% of the attendees would offer early intervention

Dr. Amrita Krishnan is an amazing mentor, colleague and a leader of the City of Hope Myeloma City of Hope | Orange County program and a national leader. Very pleased she is the SWOG chair and looking forward to the collaboration.

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine nejm.org/doi/full/10.10…

Rahul Banerjee, MD, FACP Hamza Hashmi That would be the hope in the near future! Right now, the segmentaiton software are readily integrated into the workflow but semi automated. Already some exciting work on fully automated segmentation/volumetric algorithms: pubmed.ncbi.nlm.nih.gov/38456971/?dopt… pubmed.ncbi.nlm.nih.gov/39716447/?dopt…

Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance NEJM nejm.org/doi/full/10.10… 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and

Congratulations Vincent Rajkumar Shaji Kumar! Such a lucid and practical review of a field that is getting ever so complex! 👏👏👏

OFFICIAL: The National Academy of Engineering inducts the Class of 2025! We are proud to welcome 129 new members and 21 new international members. Congratulations to the NAE Class of 2025! #NAEAnnualMeeting #NAE2025

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”